Evan Seigerman
Stock Analyst at BMO Capital
(3.33)
# 754
Out of 4,479 analysts
86
Total ratings
47.69%
Success rate
2.44%
Average return
Main Sectors:
18 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IRON Disc Medicine | Reiterates: Outperform | $50 → $70 | $46.47 | +50.63% | 5 | Jun 17, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $480 → $500 | $471.25 | +6.10% | 11 | May 31, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Market Perform | $129 → $138 | $140.11 | -1.51% | 8 | May 2, 2024 | |
| LLY Eli Lilly | Maintains: Outperform | $900 → $1,001 | $914.37 | +9.47% | 6 | May 1, 2024 | |
| INCY Incyte | Maintains: Market Perform | $56 → $52 | $60.87 | -14.57% | 6 | May 1, 2024 | |
| BMY Bristol-Myers Squibb Company | Maintains: Market Perform | $55 → $48 | $41.30 | +16.22% | 7 | Apr 26, 2024 | |
| BIIB Biogen | Maintains: Outperform | $295 → $285 | $231.77 | +22.97% | 11 | Feb 14, 2024 | |
| GILD Gilead Sciences | Upgrades: Outperform | $90 → $100 | $68.64 | +45.69% | 8 | May 16, 2023 | |
| GPCR Structure Therapeutics | Initiates: Outperform | $40 | $40.00 | - | 1 | Feb 28, 2023 | |
| REPL Replimune Group | Maintains: Outperform | $30 → $40 | $9.36 | +327.35% | 1 | Oct 14, 2022 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $757 → $788 | $1,057.02 | -25.45% | 9 | Aug 4, 2022 | |
| NUVB Nuvation Bio | Downgrades: Market Perform | $8 → $2.5 | $3.16 | -20.89% | 2 | Aug 2, 2022 | |
| AMGN Amgen | Maintains: Market Perform | $263 → $243 | $311.01 | -21.87% | 5 | Apr 28, 2022 | |
| CADL Candel Therapeutics | Maintains: Outperform | $18 → $12 | $6.30 | +90.48% | 1 | Mar 31, 2022 | |
| PFE Pfizer | Initiates: Outperform | n/a | $28.22 | - | 1 | Nov 19, 2021 | |
| IKNA Ikena Oncology | Initiates: Outperform | n/a | $1.65 | - | 1 | Apr 20, 2021 | |
| GRTX Galera Therapeutics | Upgrades: Outperform | n/a | $0.13 | - | 2 | Dec 16, 2020 | |
| MGNX MacroGenics | Maintains: Outperform | n/a | $4.30 | - | 1 | May 6, 2020 |
Disc Medicine
Jun 17, 2024
Reiterates: Outperform
Price Target: $50 → $70
Current: $46.47
Upside: +50.63%
Vertex Pharmaceuticals
May 31, 2024
Maintains: Outperform
Price Target: $480 → $500
Current: $471.25
Upside: +6.10%
Neurocrine Biosciences
May 2, 2024
Maintains: Market Perform
Price Target: $129 → $138
Current: $140.11
Upside: -1.51%
Eli Lilly
May 1, 2024
Maintains: Outperform
Price Target: $900 → $1,001
Current: $914.37
Upside: +9.47%
Incyte
May 1, 2024
Maintains: Market Perform
Price Target: $56 → $52
Current: $60.87
Upside: -14.57%
Bristol-Myers Squibb Company
Apr 26, 2024
Maintains: Market Perform
Price Target: $55 → $48
Current: $41.30
Upside: +16.22%
Biogen
Feb 14, 2024
Maintains: Outperform
Price Target: $295 → $285
Current: $231.77
Upside: +22.97%
Gilead Sciences
May 16, 2023
Upgrades: Outperform
Price Target: $90 → $100
Current: $68.64
Upside: +45.69%
Structure Therapeutics
Feb 28, 2023
Initiates: Outperform
Price Target: $40
Current: $40.00
Upside: -
Replimune Group
Oct 14, 2022
Maintains: Outperform
Price Target: $30 → $40
Current: $9.36
Upside: +327.35%
Regeneron Pharmaceuticals
Aug 4, 2022
Maintains: Outperform
Price Target: $757 → $788
Current: $1,057.02
Upside: -25.45%
Nuvation Bio
Aug 2, 2022
Downgrades: Market Perform
Price Target: $8 → $2.5
Current: $3.16
Upside: -20.89%
Amgen
Apr 28, 2022
Maintains: Market Perform
Price Target: $263 → $243
Current: $311.01
Upside: -21.87%
Candel Therapeutics
Mar 31, 2022
Maintains: Outperform
Price Target: $18 → $12
Current: $6.30
Upside: +90.48%
Pfizer
Nov 19, 2021
Initiates: Outperform
Price Target: n/a
Current: $28.22
Upside: -
Ikena Oncology
Apr 20, 2021
Initiates: Outperform
Price Target: n/a
Current: $1.65
Upside: -
Galera Therapeutics
Dec 16, 2020
Upgrades: Outperform
Price Target: n/a
Current: $0.13
Upside: -
MacroGenics
May 6, 2020
Maintains: Outperform
Price Target: n/a
Current: $4.30
Upside: -